RESUMO
Predictive factors of HCV relapse after treatment with DAAs are poorly understood. In this study, we aimed to assess whether the residual viral load positivity observed during or at the end of treatment (EOT) has an impact on viral outcome. Blood samples were collected from 337 patients with genotypes (GT) 1a, 1b, 2, 3, and 4 HCV chronic infection, treated with DAAs to determine HCV RNA load by the Abbott RealTime HCV (ART) assay at treatment week (W) 4, at EOT, and 4, 12, 24 weeks after discontinuation. EOT and other samples with "detected <12/mL" (DNQ) were retested by an ultrasensitive protocol (USP) to confirm the result. Frequency of DNQ was analyzed in subgroups of patients and clinical conditions to assess potential correlations. At W4, 22% and 30.9% of the samples were undetectable and DNQ by ART assay, respectively, but no correlation for achieving SVR was found. In contrast, an HCV RNA cut-off of ≥50/mL at W4 was a significant predictor of therapy failure (P = 0.036, univariate analysis). At EOT, DNQ was associated to 12W treatment duration (P < 0.001) and GT1a infection (P = 0.036). Overall, 20/41 (48.8%) of DNQ samples at EOT or post-treatment W4, were confirmed by USP but only in a single case the patient experienced viral relapse. HCV RNA at W4 can predict SVR, irrespective to genotype or DAA regimen. HCV RNA DNQ at EOT is associated to shorter treatment duration and to GT1a, but is not a predictor of therapy failure.
Assuntos
Hepacivirus/isolamento & purificação , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/virologia , RNA Viral/sangue , Resposta Viral Sustentada , Carga Viral , Monitoramento de Medicamentos , Feminino , Humanos , Masculino , Recidiva , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Hepatitis C virus (HCV) is classified into seven phylogenetically distinct genotypes, which are further subdivided into related subtypes. Accurate assignment of genotype/subtype is mandatory in the era of directly acting antivirals. Several molecular methods are available for HCV genotyping; however, a relevant number of samples with indeterminate, mixed, or unspecified subtype results, or even with misclassified genotypes, may occur. Using NS5B direct (DS) and ultra-deep pyrosequencing (UDPS), we have tested 43 samples, which resulted in genotype 1 unsubtyped (n = 17), mixed infection (n = 17), or indeterminate (n = 9) with the Abbott RealTime HCV Genotype II assay. Genotype 1 was confirmed in 14/17 samples (82%): eight resulted in subtype 1b, and five resulted in subtype 1a with both DS and UDPS, while one was classified as subtype 1e by DS and mixed infection (1e + 1a) by UDPS. Three of seventeen genotype 1 samples resulted in genotype 3h with both sequencing approaches. Only one mixed infection was confirmed by UDPS (4d + 1a), while in 88% of cases a single component of the mixture was detected (five genotype 1a, four genotype 1b, two genotype 3a, two genotype 4m, and two genotype 4d); 44% of indeterminate samples resulted genotype 2c by both DS and UDPS, 22% resulted genotype 3a; one indeterminate sample by Abbott resulted in genotype 4d, one resulted in genotype 6n, and one was classified as subtype 3a by DS, and resulted mixed infection (3a + 3h) by UDPS. The concordance between DS and UDPS was 94%, 88%, and 89% for genotype 1, co-infection, and indeterminate results, respectively. UDPS should be considered very useful to resolve ambiguous HCV genotyping results.
Assuntos
Hepacivirus/genética , Hepatite C/virologia , Sequenciamento de Nucleotídeos em Larga Escala , RNA Viral/química , Genótipo , Hepacivirus/metabolismo , Hepatite C/classificação , Humanos , Filogenia , RNA Viral/genética , RNA Viral/metabolismo , Kit de Reagentes para Diagnóstico , Reação em Cadeia da Polimerase em Tempo Real , Análise de Sequência de DNA , Proteínas não Estruturais Virais/genéticaRESUMO
During 2011, 5 persons in the area of Lazio, Italy were infected with a monophyletic strain of hepatitis E virus that showed high sequence homology with isolates from swine in China. Detection of this genotype in Italy parallels findings in other countries in Europe, signaling the possible spread of strains new to Western countries.
Assuntos
Surtos de Doenças , Genótipo , Vírus da Hepatite E/genética , Hepatite E/epidemiologia , RNA Viral/genética , Adulto , Idoso , China , Hepatite E/virologia , Vírus da Hepatite E/classificação , Vírus da Hepatite E/isolamento & purificação , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Tipagem Molecular , Filogenia , Filogeografia , RNA Viral/classificação , RNA Viral/isolamento & purificaçãoRESUMO
The genetic variability of E6, E7 and L1 of HPV81 from HIV-1 positive women carrying multiple HPV infections was investigated by clonal analysis for E6 and E7. The range of maximal divergence from the prototype was 0.6%-2.6% for E6 and 1.0%-3.1% for E7. Compared to prototype HPV81, 13 and 10 mutations were identified in E6 and E7, respectively. In the pRB binding domain of E7, all HPV81 clones showed D21, as reported for prototype HPV81 and for HPV16 and 18, while G22 is reported in HPV6 and 11. In the CR3 region, CxxC motif was conserved in all but one clone. The L1 sequence of a single clone from 5 study patients was also established. The range of similarity with prototype HPV81 was 97.8%-99.2%, with 25 polymorphic sites. Two substitutions (R492K and T493S) were observed in 5/5, one (T287N) in 4/5 patients. Among L1 immune-related regions, BC loop presented T56N in 1/5, while FGb loop presented T287N in 4/5 patients. Our data indicate the presence of polymorphisms in all 3 HPV81 genes analyzed, with a certain degree of intra-patient diversity. The importance of polymorphisms on HPV81 persistence and pathogenicity needs to be addressed in longitudinal studies involving larger patient numbers.